Log In
Monday 21st May 2018

Golimumab could soon be approved

4th May 2011

The National Institute of Health and Clinical Excellence (NICE) issued its final guidance recommending the anti-TNF therapy golimumab for use for psoriatic arthritis.

NICE has added golimumab, which has the brand name Simponi, to its list of recommended treatments for the condition. It works by preventing the molecule tumour necrosis factor (TNF) from binding to receptors and causing inflammation. It suggested that the treatment is a viable option for adult patients with active and progressive psoriatic arthritis if it is used in a similar way to other TNF-inhibiting treatments, such as etanercept, infliximab and adalimumab.


Share this page


There are no comments for this article, be the first to comment!

Post your comment

Only registered users can comment. Fill in your e-mail address for quick registration.

Your email address:

Your comment will be checked by a Healthcare Today moderator before it is published on the site.

Article Information

Title: Golimumab could soon be approved
Author: Mark Nicholls
Article Id: 18357
Date Added: 4th May 2011


Arthritis Research UK

Recent Related Articles

Exercises to lower arthritis pain

Uncommon rheumatoid arthritis sign linked to eyes


Add to scrapbook
Show Comments
Add comment
Find all related articles


Mayden - Innovative cloud-based applications for healthcare
© Mayden Foundation 2018